House dust mite allergy vaccine - Allergopharma

Drug Profile

House dust mite allergy vaccine - Allergopharma

Alternative Names: Acaroid; Dermatophagoides pteronyssinus allergoids

Latest Information Update: 07 Mar 2016

Price : $50

At a glance

  • Originator Allergopharma
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis

Most Recent Events

  • 07 Mar 2012 Allergopharma Joachim Ganzer KG initiates enrolment in a phase II trial for Allergic asthma in Poland (EudraCT 2011-002248-29)
  • 07 Mar 2012 Phase-II clinical trials in Allergic asthma in Poland (SC) (EudraCT 2011-002248-29)
  • 24 Jun 2010 Suspended - Phase-III for Allergic rhinitis in Bulgaria (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top